Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

IntegenX selects Zeta's 3D to analyze dimensional properties of micro-channel biochips

Zeta Instruments, Inc. a leading provider of cost-effective, precision measurement solutions for micron-scale surface analysis, announced that its Zeta-20™ optical metrology system has been selected for the analysis and development of advanced microfluidics/biotechnology laboratory products. IntegenX, an innovative supplier of automation systems for DNA and RNA-based micro-sample preparation used in forensics and gene sequencing, has chosen Zeta's 3D surface measurement solution to analyze the dimensional properties of its micro-channel biochips.

3 Aug 2010

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

3 Aug 2010

BioMarin reports $0.5 million GAAP net loss for second-quarter 2010

BioMarin Pharmaceutical Inc. today announced financial results for the second quarter of 2010. GAAP net loss was $0.5 million ($0.01 per diluted share) for the second quarter of 2010, compared to GAAP net income of $1.3 million ($0.01 per diluted share) for the second quarter of 2009. Non-GAAP net income was $8.6 million ($0.08 per diluted share) for the second quarter of 2010, compared to non-GAAP net income of $9.0 million ($0.09 per diluted share) for the second quarter of 2009.

3 Aug 2010

Orthovita second-quarter operating income improves to $0.4 million

Orthovita, Inc., an orthobiologics and biosurgery company, reported financial results for the quarter ended June 30, 2010. Product sales for the second quarter of 2010 were $23.9 million compared to $24.5 million for the second quarter of 2009. Product sales for the second quarter of 2009 included $0.6 million from the sale of Vitomatrix™, a bone graft material used in dental products. There were no Vitomatrix sales in the second quarter of 2010 and no further sales of Vitomatrix are currently expected.

3 Aug 2010

RoundTable announces establishment of new platform business in ophthalmology market

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has established a platform business in the ophthalmology market. The new platform company, Beaver-Visitec International, Inc., consists of ophthalmology products and assets recently acquired from BD and Medtronic, Inc.

2 Aug 2010

MannKind second-quarter total operating expenses decrease to $16.0 million

MannKind Corporation today reported financial results for the second quarter ended June 30, 2010.

2 Aug 2010

INEOS agrees to sell Global Films business to Bilcare AG

INEOS Group has today entered into a binding agreement for the sale of its Global Films business to Bilcare AG, one of the world's leading providers of research led packaging to the global pharmaceuticals industry, for approximately EUR100 million. The agreement brings together complimentary capabilities and synergy's of two leading global businesses.

2 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Perrigo files ANDA for butoconazole nitrate vaginal cream

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company, the owner of the New Drug Application as well as FemmePharma, the listed owner of the patent, of its ANDA filing. KV is a licensee under the patent. Perrigo believes it is first-to-file on this product.

31 Jul 2010

Nuvo Research second-quarter revenue increases 57% to $4.2 million

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Angiotech reports $61.9 million total revenue for second-quarter 2010

Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

31 Jul 2010

Sodium Working Group recommends reducing sodium intake among Canadians

The federally-mandated Sodium Working Group has released the Sodium Reduction Strategy for Canada. The three-pronged strategy contains six over-arching and 27 specific recommendations for a population health strategy for reducing sodium intake among Canadians.

31 Jul 2010

Vitacost.com second-quarter net sales increase 14% to $54.0 million

Vitacost.com, Inc., a leading online retailer and direct marketer of health and wellness products, today reported preliminary financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Research Roundup:COBRA subsidies; Children's insurance and dental coverage; Adopting health IT; Race and heart treatments

Archives of Internal Medicine: Racial Differences In Admissions To High-Quality Hospitals For Coronary Heart Disease - "Racial disparities in the management of coronary heart disease (CHD) are widely documented, yet the reasons behind persistent gaps in quality of care are not fully understood," write the authors, who examined "Medicare patients with acute myocardial infarction and coronary artery bypass grafting (CABG) admitted during 2002 through 2005 to hospitals located in markets with top-ranked cardiac hospitals, as ascertained from the US News and World Report 'America's Best Hospitals' annual rankings."

31 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

Palomar Medical second-quarter product and service revenues increase 8% to $13.0 million

Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the second quarter ended June 30, 2010. Revenues for the quarter ended June 30, 2010 were $15.6 million, which represents a 4 percent increase over the $15.0 million reported in the second quarter of 2009. Product and service revenues increased to $13.0 million, an 8 percent increase over the $12.1 million in the second quarter of 2009.

30 Jul 2010

National Dentex completes Merger Agreement

National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.

30 Jul 2010